Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public health priorities and clinical paradigms are shifting rapidly, this issue highlights the importance of evidence-based […]

EUROPEAN ENDOCRINE DISEASE – VOLUME 3 ISSUE 1 – SUMMER 2007

Select a Section…
1

Foreword

Diabetes, like other chronic illnesses, requires patients to absorb a daunting amount of information in a limited amount of time and make significant lifestyle changes. For many patients, it is the first time they have heard of terms such as hyperglycaemia, neuropathy, microalbuminuria or even blood glucose. Despite their unfamiliarity with these terms and others, […]

2

Current Issues

Resolution 61/225: ‘World Diabetes Day’ recognizes diabetes as a chronic, debilitating, and costly disease associated with major complications that pose severe risks for families, countries, and the entire world. It designates 14 November, the current World Diabetes Day, as a United Nations Day to be observed every year beginning in 2007. The Campaign for a […]

According to the last American Diabetes Association (ADA) recommendations, it is possible to demonstrate an abnormality in carbohydrate metabolism, diagnostic for diabetes, by measurement of fasting plasma glucose (glycaemia ≥126mg/dl, i.e. ≥7.0mmol/l) or after a challenge with an oral glucose load (OGTT) (glycemia ≥200mg/dl two hours post an oral 75g glucose challenge, i.e. ≥11.1mmol/l) or […]

3

Incretin Mimetics

Unlike GLP-1, which has a halflife too short to make it viable for treatment, exenatide is resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Exenatide has shown to increase glucose-dependent insulin secretion, decrease glucose-dependent post-prandial secretion of glucagon, slow gastric emptying and reduce food intake. Furthermore, some of these effects represent mechanisms that have […]

4

Insulin Therapy in Uncontrolled Type 2 Diabetes

The timely addition of insulin to an oral agent regimen along with close attention to its optimal dosing will lead to better glucose control, which will translate into better health for these patients.T2DM is associated with enormous morbidity and mortality. In the US, it contributes to more cases of adult-onset loss of vision, renal failure […]

Large-scale clinical trials have demonstrated the benefits of tight control in type 2 diabetes, minimising disease complications and improving quality of life.1,2 Recognising the progressive nature of type 2 diabetes, treatment programmes incorporating the use of insulin earlier in its course are receiving increasing attention.

However, prevention of high blood glucose (BG) and maintenance of glycated haemoglobin A1C <7.0% have been demonstrated to reduce the incidence of all complications of T2DM. Therefore, it is essential that T2DM is not only prevented (i.e. by tackling obesity and implementing an active lifestyle), but is also diagnosed early and treated aggressively from its […]

5

DPP-4 Inhibitors

1–3 GLP-1 and GIP also stimulate (3-cell proliferation, promote resistance to apoptosis and ncrease (3-cell survival, thus increasing (3-cell mass and function in the long term.1 Furthermore, GLP-1 inhibits glucagon secretion and reduces food intake through the inhibition of gastric emptying and through a direct hypothalamic effect.1 All of these actions of GIP and GLP-1 […]

In addition, it delays gastric emptying4 and, when infused in pharmacological concentrations, enhances satiation and facilitates weight loss in people with T2DM.5 However, its utility as a therapeutic agent in T2DM has been limited by its extremely short half-lifeThe major form of secreted GLP-1, GLP-1-(7,36)-amide, requires the presence of the two N-terminal amino acids for […]

6

Diabetes and Cardiovascular Risk

How to Evaluate the Cardiovascular Risk in Patients with Diabetes? 

Cardiometabolic risk is particularly prevalent in patients diagnosed as having metabolic syndrome.

7

Diabetic Nephropathy

Therapies that are proved to delay or prevent this outcome will clearly be of major benefitThe aetiology of DN is unknown. Hyperglycaemia is necessary but not sufficient to develop this complication, as is well demonstrated by observations in subjects with T1DM.

Diabetic nephropathy-characterized by hypertension, macro-albuminuria, progressive loss of renal function, and a high incidence of cardiovascular morbidity and mortality-is the leading cause of end-stage renal failure in the US.1-5 The predictive power of proteinuria for progressive renal function loss has been demonstrated in patients with and without diabetic nephropathy.6,7 It has been suggested, therefore, that […]

8

Diabetic Neuropathy

9

Diabetes & Sleep Apnoea

These findings suggest a significant overlap between the two diseases, but this clinic-based sample of obese patients (body mass index (BMI) 30.6±0.2) had been selected on the basis of presentation with typical symptoms of OSAS.

10

Testosterone Replacement Therapy

Such beneficia therapeutic effects on CV risk factors now need to be confirmed in larger, longer term trials, as does safety. The diagnosis of clinically relevant hypogonadism will be discussed in the light of the recent evidence and current clinical guidelinesLow circulating levels of testosterone are frequently found in men with the metabolic syndrome and […]

11

Thyroid Disorders

Questions remain unanswered concerning differentiated-thyroid carcinoma •    What is the role and optimal extent of surgery? •    What is the role of adjuvant therapy? •    What is the role of thyroid hormone therapy? •    What is the optimal monitoring therapy?

In both papers, new tools introduced in the last 10 years have been integrated Both the American and European expert panels propose a risk-dependent strategy:•    recombinant human thyroid-stimulating hormone (rhTSH) as an alternative for the withdrawal (WD) of thyroid hormone in order to obtain a high thyroid-stimulating hormone (TSH);6 and

Hyperthyroidism mainly affects the female population, occurring in around 2% of women and 0.2% of men.1 The majority of patients with hyperthyroidism have Graves’ disease (GD) and, less often, solitary toxic nodule or toxic multinodular goitre. Other causes of hyperthyroidism are relatively rare and are summarised in Table 1.

This concentration gradient may be more than 100:1 in a hyperactive thyroid, as seen in patients with Graves’ disease. The daily intake of an adult human varies from less than 10mg in areas of extreme iodine deficiency to several hundred milligrams for some people receiving medicinal iodine.

12

Gynaecological Endocrinology

PM may be iatrogenic, i.e. secondary to surgical remova of both ovaries (bilateral oophorectomy), or to the irreversible ovarian damage caused by chemotherapy or radiotherapy, either pelvic or total body irradiation.1–9 POF currently encompasses all modalities of ovarian exhaustion when the ovaries remain on-siteSurgical menopause suddenly deprives the woman of total ovarian hormone production. POF, […]

Obtaining a Diagnosis of the Patient with Possible Polycystic Ovary SyndromeWhenever attempting to diagnose PCOS, it is important to define the population at high risk for having the syndrome. Women with unwanted hair growth7,8 or menstrual disturbances9,10 are highly likely to have PCOS.11,12

13

Erectile Dysfunction

Physiology of Normal Penile Erection

14
View All Issues

touchREVIEWS in Endocrinology (previously European Endocrinology) is a peer-reviewed, free-to-access, bi-annual journal comprising review articles, case reports, editorials, special reports and original research. It features balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the field of endocrinology.

Close Popup